Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09

Giapreza(angiotensin II acetate)

Hypotension;Shock

Marketing Authorisation Holder: Paion Pharma GmbH

EMA Authorisation: 23/08/2019

INN: angiotensin II

Indication

Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Giapreza — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.